Geron
This article was originally published in The Gray Sheet
Executive Summary
Sale of $25 mil. in zero coupon convertible debentures to an existing institutional investor under an agreement announced June 29 brings total cash on hand to approximately $98 mil. This "should allow us to continue investing in our telomerase drug discovery, stem cell and nuclear transfer development programs," Geron explains. The Menlo Park, California firm stem cell R&D is focused on discovering, developing and commercializing therapeutic and diagnostic products for applications in oncology, research tools for drug discovery and regenerative medicine